Liraglutide lowered NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in KCs and decreased mitochondrial dysfunction, leading to an important reduction in IL-1β, IL-12, and tumor necrosis factor-α (TNF-α) expression levels, while increasing the expression of IL-10 [47,48]. The gene discussed is NLRP3; the disease is dry eye syndrome.